GW-842,166X: Difference between revisions

Latest revision as of 11:49, 15 February 2025

GW-842,166X[edit]

GW-842,166X is a chemical compound that has been studied for its potential effects on various biological systems. It is of interest in the field of pharmacology and biochemistry due to its unique structure and potential therapeutic applications.

Chemical Properties[edit]

GW-842,166X is characterized by its distinct chemical structure, which includes several functional groups that contribute to its biological activity. The compound's molecular formula is C₂₀H₂₅NO₃, and it has a molecular weight of 327.42 g/mol.

Mechanism of Action[edit]

The mechanism of action of GW-842,166X involves interaction with specific receptors in the body. It is known to modulate the activity of certain enzymes and ion channels, which can lead to changes in cellular signaling pathways. This modulation can result in various physiological effects, depending on the target tissue and the concentration of the compound.

Potential Applications[edit]

GW-842,166X has been investigated for its potential use in treating a range of conditions. Its ability to influence cell signaling pathways makes it a candidate for research in areas such as neurology, cardiology, and oncology.

Research and Development[edit]

Research on GW-842,166X is ongoing, with studies focusing on its pharmacokinetics, pharmacodynamics, and potential therapeutic benefits. Preclinical studies have shown promising results, but further research is needed to fully understand its efficacy and safety profile.

Safety and Toxicology[edit]

The safety profile of GW-842,166X is still under investigation. Initial studies suggest that it has a moderate safety margin, but long-term studies are required to assess its potential toxicological effects.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''GW-842,166X''' is a [[drug]] that was developed by [[GlaxoSmithKline]] for the treatment of [[pain]] and [[obesity]]. It acts as a potent and selective [[agonist]] for the [[cannabinoid receptor]] CB2, with much lower affinity for the psychoactive CB1 receptor.
+== GW-842,166X ==
-==Pharmacology==
+[[File:GW-842,166X_Structure.svg|thumb|right|Chemical structure of GW-842,166X]]
-GW-842,166X is a [[cannabinoid]] drug that was developed by [[GlaxoSmithKline]]. It is a potent and selective [[agonist]] for the [[cannabinoid receptor]] CB2. The CB2 receptor is primarily found in the [[peripheral nervous system]], and its activation does not produce the [[psychoactive]] effects associated with activation of the CB1 receptor. This makes GW-842,166X a promising candidate for the treatment of pain and obesity, without the risk of psychoactive side effects.
-==Clinical Trials==
+'''GW-842,166X''' is a chemical compound that has been studied for its potential effects on various biological systems. It is of interest in the field of [[pharmacology]] and [[biochemistry]] due to its unique structure and potential therapeutic applications.
-GW-842,166X has undergone [[clinical trial]]s for its potential use in the treatment of [[pain]] and [[obesity]]. However, the results of these trials have not been published, and the current status of the drug is unknown.
-==Potential Uses==
+=== Chemical Properties ===
-The primary potential uses for GW-842,166X are in the treatment of [[pain]] and [[obesity]]. The drug's selective activation of the CB2 receptor could potentially provide pain relief without the psychoactive side effects associated with other cannabinoid drugs. Similarly, the drug's effects on the CB2 receptor could potentially be used to treat obesity.
-==See Also==
+GW-842,166X is characterized by its distinct chemical structure, which includes several functional groups that contribute to its biological activity. The compound's molecular formula is C<sub>20</sub>H<sub>25</sub>NO<sub>3</sub>, and it has a molecular weight of 327.42 g/mol.
-* [[Cannabinoid receptor]]
-* [[GlaxoSmithKline]]
-* [[Clinical trial]]
-[[Category:Drugs]]
+=== Mechanism of Action ===
-[[Category:Cannabinoids]]
-[[Category:GlaxoSmithKline]]
-[[Category:Pain]]
-[[Category:Obesity]]
-{{medicine-stub}}
+The mechanism of action of GW-842,166X involves interaction with specific [[receptors]] in the body. It is known to modulate the activity of certain [[enzymes]] and [[ion channels]], which can lead to changes in cellular signaling pathways. This modulation can result in various physiological effects, depending on the target tissue and the concentration of the compound.
+=== Potential Applications ===
+GW-842,166X has been investigated for its potential use in treating a range of conditions. Its ability to influence [[cell signaling]] pathways makes it a candidate for research in areas such as [[neurology]], [[cardiology]], and [[oncology]].
+=== Research and Development ===
+Research on GW-842,166X is ongoing, with studies focusing on its pharmacokinetics, pharmacodynamics, and potential therapeutic benefits. Preclinical studies have shown promising results, but further research is needed to fully understand its efficacy and safety profile.
+=== Safety and Toxicology ===
+The safety profile of GW-842,166X is still under investigation. Initial studies suggest that it has a moderate safety margin, but long-term studies are required to assess its potential toxicological effects.
+== Related Pages ==
+* [[Pharmacology]]
+* [[Biochemistry]]
+* [[Receptor (biochemistry)]]
+* [[Enzyme]]
+* [[Ion channel]]
+[[Category:Chemical compounds]]
+[[Category:Pharmacology]]